Semin Thromb Hemost 2023; 49(03): 295-304
DOI: 10.1055/s-0042-1760333
Review Article

Evolution of Antiphospholipid Syndrome

Deepa R.J. Arachchillage
1   Department of Immunology and Inflammation, Centre for Haematology, Imperial College London, London, United Kingdom
2   Department of Haematology, Imperial College Healthcare NHS Trust, London, United Kingdom
Charis Pericleous
3   National Heart and Lung Institute, Imperial College London, London, United Kingdom
› Author Affiliations
Funding This article is not funded by any external sources. However, D.J A is funded by MRC UK (MR/V037633/1) and C.P. is funded by Versus Arthritis (21223) and the Imperial College-Wellcome Trust Institutional Strategic Support Fund.


Antiphospholipid syndrome (APS) is an autoimmune prothrombotic disease characterized by thrombosis and/or pregnancy complications caused by antiphospholipid antibodies (aPL). The history of APS can be traced back to observations made during screening programs for syphilis conducted in the mid-20th century, with identification of patients with the so-called biological false-positive serological reactions for syphilis. Initial observation linking aPL with recurrent miscarriages was first reported more than 40 years ago. Since then, our understanding of the pathogenesis and management of APS has evolved markedly. Although APS is an autoimmune disease, anticoagulation mainly with vitamin K antagonists (VKAs) rather than immunomodulation, is the treatment of choice for thrombotic APS. Direct acting oral anticoagulants are inferior to VKAs, especially those with triple-positive APS and arterial thrombosis. Inflammation, complement activation, and thrombosis in the placenta may contribute to pathogenesis of obstetric APS. Heparin, mainly low-molecular-weight heparin, and low-dose aspirin represent the treatments of choice for women with obstetric complications. Increasingly, immunomodulatory agents such as hydroxychloroquine for thrombotic and obstetric APS are being used, especially in patients who are refractory to present standard treatment.

Publication History

Article published online:
16 January 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

  • References

  • 1 Miyakis S, Lockshin MD, Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4 (02) 295-306
  • 2 Pengo V, Ruffatti A, Legnani C. et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010; 8 (02) 237-242
  • 3 Wasserman A, Neisser A, Bruck C. Eine serodiagnostiche reaction bei syphilis. Dtsch Med Wochenschr 1906; 32: 745-749
  • 4 Landsteiner K, Muller R, Potzl D. Studies on the complement binding reaction in syphilis. Wien Klin Wochenschr 1907; 20: 1565-1567
  • 5 Pangborn MC. A new serologically active phospholipid from beef heart. Proc Soc Exp Biol Med 1941; 48: 484-486
  • 6 Pangborn MC. Isolation and purification of a serologically active phospholipid from beef heart. J Biol Chem 1942; 143: 247-256
  • 7 Moore JE, Mohr CF. The incidence and etiologic background of chronic biologic false-positive reactions in serologic tests for syphilis. Ann Intern Med 1952; 37 (06) 1156-1161
  • 8 Moore JE, Lutz WB. The natural history of systemic lupus erythematosus: an approach to its study through chronic biologic false positive reactors. J Chronic Dis 1955; 1 (03) 297-316
  • 9 Harvey AM, Shulman LE, Tumulty PA, Conley CL, Schoenrich EH. Systemic lupus erythematosus: review of the literature and clinical analysis of 138 cases. Medicine (Baltimore) 1954; 33 (04) 291-437
  • 10 Harvey AM. Auto-immune disease and the chronic biologic false-positive test for syphilis. JAMA 1962; 182: 513-518
  • 11 Knight A, Wilkinson RD. The clinical significance of the biological false positive serologic reactor: a study of 113 cases. Can Med Assoc J 1963; 88 (24) 1193-1195
  • 12 Aggeler PM, Lindsay S, Lucia SP. Studies on the coagulation defect in a case of thrombocytopenic purpura complicated by thrombosis. Am J Pathol 1946; 22 (06) 1181-1203
  • 13 Ley AB, Reader GG, Sorenson CW, Overman RS. Idiopathic hypoprothrombinemia associated with hemorrhagic diathesis, and the effect of vitamin K. Blood 1951; 6 (08) 740-755
  • 14 Frick PG. Acquired circulating anticoagulants in systemic collagen disease; auto-immune thromboplastin deficiency. Blood 1955; 10 (07) 691-706
  • 15 Conley CL, Hartmann RC. A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J Clin Invest 1952; 21: 1-2
  • 16 Lee SL, Sanders M. A disorder of blood coagulation in systemic lupus erythematosus. J Clin Invest 1955; 34 (12) 1814-1822
  • 17 Laurell AB, Nilsson IM. Hypergammaglobulinemia, circulating anticoagulant, and biologic false positive Wassermann reaction; a study in two cases. J Lab Clin Med 1957; 49 (05) 694-707
  • 18 Feinstein DI, Rapaport SI. Acquired inhibitors of blood coagulation. Prog Hemost Thromb 1972; 1: 75-95
  • 19 Thiagarajan P, Shapiro SS, De Marco L. Monoclonal immunoglobulin M lambda coagulation inhibitor with phospholipid specificity. Mechanism of a lupus anticoagulant. J Clin Invest 1980; 66 (03) 397-405
  • 20 Thiagarajan P, Pengo V, Shapiro SS. The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants. Blood 1986; 68 (04) 869-874
  • 21 Alving CR, Kinsky SC, Haxby JA, Kinsky CB. Antibody binding and complement fixation by a liposomal model membrane. Biochemistry 1969; 8 (04) 1582-1587
  • 22 Smolarsky M. A simple radioimmunoassay to determine binding of antibodies to lipid antigens. J Immunol Methods 1980; 38 (1-2): 85-93
  • 23 Harris EN, Gharavi AE, Boey ML. et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983; 2 (8361): 1211-1214
  • 24 Loizou S, McCrea JD, Rudge AC, Reynolds R, Boyle CC, Harris EN. Measurement of anti-cardiolipin antibodies by an enzyme-linked immunosorbent assay (ELISA): standardization and quantitation of results. Clin Exp Immunol 1985; 62 (03) 738-745
  • 25 Sanchez Medal L, Lisker R. Circulating anticoagulants in disseminated lupus erythematosus. Br J Haematol 1959; 5: 284-293
  • 26 Bowie EJ, Thompson Jr JH, Pascuzzi CA, Owen Jr CA. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Lab Clin Med 1963; 62: 416-430
  • 27 Green D, Rizza CR. Myocardial infarction in a patient with a circulating anticoagulant. Lancet 1967; 2 (7513): 434-436
  • 28 Boey ML, Colaco CB, Gharavi AE, Elkon KB, Loizou S, Hughes GR. Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant. Br Med J (Clin Res Ed) 1983; 287 (6398): 1021-1023
  • 29 Manoharan A, Gibson L, Rush B, Feery BJ. Recurrent venous thrombosis with a “lupus” coagulation inhibitor in the absence of systemic lupus. Aust N Z J Med 1977; 7 (04) 422-426
  • 30 Nilsson IM, Astedt B, Hedner U, Berezin D. Intrauterine death and circulating anticoagulant (“antithromboplastin”). Acta Med Scand 1975; 197 (03) 153-159
  • 31 Firkin BG, Howard MA, Radford N. Possible relationship between lupus inhibitor and recurrent abortion in young women. Lancet 1980; 2 (8190): 366
  • 32 Lubbe WF, Walker EB. Chorea gravidarum associated with circulating lupus anticoagulant: successful outcome of pregnancy with prednisone and aspirin therapy. Case report. Br J Obstet Gynaecol 1983; 90 (05) 487-490
  • 33 Hughes GR. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. Br Med J (Clin Res Ed) 1983; 287 (6399): 1088-1089
  • 34 Lockshin MD, Druzin ML, Goei S. et al. Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus. N Engl J Med 1985; 313 (03) 152-156
  • 35 Branch DW, Scott JR, Kochenour NK, Hershgold E. Obstetric complications associated with the lupus anticoagulant. N Engl J Med 1985; 313 (21) 1322-1326
  • 36 Asherson RA, Mackworth-Young CG, Harris EN, Gharavi AE, Hughes GR. Multiple venous and arterial thromboses associated with the lupus anticoagulant and antibodies to cardiolipin in the absence of SLE. Rheumatol Int 1985; 5 (02) 91-93
  • 37 Mackworth-Young CG, Loizou S, Walport MJ. Primary antiphospholipid syndrome: features of patients with raised anticardiolipin antibodies and no other disorder. Ann Rheum Dis 1989; 48 (05) 362-367
  • 38 Asherson RA, Khamashta MA, Ordi-Ros J. et al. The “primary” antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore) 1989; 68 (06) 366-374
  • 39 Alarcón-Segovia D, Delezé M, Oria CV. et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine (Baltimore) 1989; 68 (06) 353-365
  • 40 Bird AG, Lendrum R, Asherson RA, Hughes GR. Disseminated intravascular coagulation, antiphospholipid antibodies, and ischaemic necrosis of extremities. Ann Rheum Dis 1987; 46 (03) 251-255
  • 41 Ingram SB, Goodnight Jr SH, Bennett RM. An unusual syndrome of a devastating noninflammatory vasculopathy associated with anticardiolipin antibodies: report of two cases. Arthritis Rheum 1987; 30 (10) 1167-1172
  • 42 Bendon RW, Wilson J, Getahun B, van der Bel-Kahn J. A maternal death due to thrombotic disease associated with anticardiolipin antibody. Arch Pathol Lab Med 1987; 111 (04) 370-372
  • 43 Brown JH, Doherty CC, Allen DC, Morton P. Fatal cardiac failure due to myocardial microthrombi in systemic lupus erythematosus. Br Med J (Clin Res Ed) 1988; 296 (6635): 1505
  • 44 Asherson RA. The catastrophic antiphospholipid syndrome. J Rheumatol 1992; 19 (04) 508-512
  • 45 McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 1990; 87 (11) 4120-4124
  • 46 Galli M, Comfurius P, Maassen C. et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335 (8705): 1544-1547
  • 47 Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990; 336 (8708): 177-178
  • 48 Matsuura E, Igarashi M, Igarashi Y. et al. Molecular definition of human beta 2-glycoprotein I (beta 2-GPI) by cDNA cloning and inter-species differences of beta 2-GPI in alternation of anticardiolipin binding. Int Immunol 1991; 3 (12) 1217-1221
  • 49 Meroni PL, Borghi MO, Raschi E, Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol 2011; 7 (06) 330-339
  • 50 Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med 2013; 368 (11) 1033-1044
  • 51 McDonnell T, Wincup C, Buchholz I. et al. The role of beta-2-glycoprotein I in health and disease associating structure with function: more than just APS. Blood Rev 2020; 39: 100610
  • 52 Steinkasserer A, Estaller C, Weiss EH, Sim RB, Day AJ. Complete nucleotide and deduced amino acid sequence of human beta 2-glycoprotein I. Biochem J 1991; 277 (Pt 2): 387-391
  • 53 Schwarzenbacher R, Zeth K, Diederichs K. et al. Crystal structure of human beta2-glycoprotein I: implications for phospholipid binding and the antiphospholipid syndrome. EMBO J 1999; 18 (22) 6228-6239
  • 54 de Laat B, Derksen RH, van Lummel M, Pennings MT, de Groot PG. Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change. Blood 2006; 107 (05) 1916-1924
  • 55 Pericleous C, Rahman A. Domain I: the hidden face of antiphospholipid syndrome. Lupus 2014; 23 (12) 1320-1323
  • 56 Kelchtermans H, Chayouâ W, Laat B. The significance of antibodies against domain I of beta-2 glycoprotein I in antiphospholipid syndrome. Semin Thromb Hemost 2018; 44 (05) 458-465
  • 57 Durigutto P, Grossi C, Borghi MO. et al. New insight into antiphospholipid syndrome: antibodies to β2glycoprotein I-domain 5 fail to induce thrombi in rats. Haematologica 2019; 104 (04) 819-826
  • 58 Andreoli L, Chighizola CB, Nalli C. et al. Clinical characterization of antiphospholipid syndrome by detection of IgG antibodies against β2-glycoprotein I domain 1 and domain 4/5: ratio of anti-domain 1 to anti-domain 4/5 as a useful new biomarker for antiphospholipid syndrome. Arthritis Rheumatol 2015; 67 (08) 2196-2204
  • 59 Roggenbuck D, Borghi MO, Somma V. et al. Antiphospholipid antibodies detected by line immunoassay differentiate among patients with antiphospholipid syndrome, with infections and asymptomatic carriers. Arthritis Res Ther 2016; 18 (01) 111
  • 60 Agostinis C, Durigutto P, Sblattero D. et al. A non-complement-fixing antibody to β2 glycoprotein I as a novel therapy for antiphospholipid syndrome. Blood 2014; 123 (22) 3478-3487
  • 61 Pericleous C, Ruiz-Limón P, Romay-Penabad Z. et al. Proof-of-concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of β2-glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis. Rheumatology (Oxford) 2015; 54 (04) 722-727
  • 62 Pericleous C, Ferreira I, Borghi O. et al. Measuring IgA anti-β2-glycoprotein I and IgG/IgA anti-domain I antibodies adds value to current serological assays for the antiphospholipid syndrome. PLoS One 2016; 11 (06) e0156407
  • 63 de Laat B, Derksen RH, Urbanus RT, de Groot PG. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 2005; 105 (04) 1540-1545
  • 64 De Craemer AS, Musial J, Devreese KM. Role of anti-domain 1-β2 glycoprotein I antibodies in the diagnosis and risk stratification of antiphospholipid syndrome. J Thromb Haemost 2016; 14 (09) 1779-1787
  • 65 Radin M, Cecchi I, Roccatello D, Meroni PL, Sciascia S. Prevalence and thrombotic risk assessment of anti-β2 glycoprotein I domain I antibodies: a systematic review. Semin Thromb Hemost 2018; 44 (05) 466-474
  • 66 Pericleous C, D'Souza A, McDonnell T. et al. Antiphospholipid antibody levels in early systemic lupus erythematosus: are they associated with subsequent mortality and vascular events?. Rheumatology (Oxford) 2020; 59 (01) 146-152
  • 67 Farina N, Abdulsalam R, McDonnell T. et al. Antiphospholipid antibody positivity in early systemic lupus erythematosus is associated with subsequent vascular events. Rheumatology (Oxford) 2022; keac596 DOI: 10.1093/rheumatology/keac596.
  • 68 Chighizola CB, Pregnolato F, Andreoli L. et al. Beyond thrombosis: anti-β2GPI domain 1 antibodies identify late pregnancy morbidity in anti-phospholipid syndrome. J Autoimmun 2018; 90: 76-83
  • 69 Iverson GM, Reddel S, Victoria EJ. et al. Use of single point mutations in domain I of beta 2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies. J Immunol 2002; 169 (12) 7097-7103
  • 70 Ioannou Y, Pericleous C, Giles I, Latchman DS, Isenberg DA, Rahman A. Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43. Arthritis Rheum 2007; 56 (01) 280-290
  • 71 de Laat B, van Berkel M, Urbanus RT. et al. Immune responses against domain I of β(2)-glycoprotein I are driven by conformational changes: domain I of β(2)-glycoprotein I harbors a cryptic immunogenic epitope. Arthritis Rheum 2011; 63 (12) 3960-3968
  • 72 Iverson GM, Victoria EJ, Marquis DM. Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci U S A 1998; 95 (26) 15542-15546
  • 73 Radin M, Foddai SG, Cecchi I. et al. Antiphosphatidylserine/prothrombin antibodies: an update on their association with clinical manifestations of antiphospholipid syndrome. Thromb Haemost 2020; 120 (04) 592-598
  • 74 Pregnolato F, Chighizola CB, Encabo S. et al. Anti-phosphatidylserine/prothrombin antibodies: an additional diagnostic marker for APS?. Immunol Res 2013; 56 (2-3): 432-438
  • 75 Žigon P, Perdan Pirkmajer K, Tomšič M. et al. Anti-phosphatidylserine/prothrombin antibodies are associated with adverse pregnancy outcomes. J Immunol Res 2015; 2015: 975704
  • 76 Marchetti T, de Moerloose P, Gris JC. Antiphospholipid antibodies and the risk of severe and non-severe pre-eclampsia: the NOHA case-control study. J Thromb Haemost 2016; 14 (04) 675-684
  • 77 Shi H, Zheng H, Yin YF. et al. Antiphosphatidylserine/prothrombin antibodies (aPS/PT) as potential diagnostic markers and risk predictors of venous thrombosis and obstetric complications in antiphospholipid syndrome. Clin Chem Lab Med 2018; 56 (04) 614-624
  • 78 Pham M, Orsolini G, Crowson C, Snyder M, Pruthi R, Moder K. Anti-phosphatidylserine prothrombin antibodies as a predictor of the lupus anticoagulant in an all-comer population. J Thromb Haemost 2022; 20 (09) 2070-2074
  • 79 Noble H, Crossette-Thambiah C, Odho Z. et al. Frequency and clinical significance anti-PS/PT antibodies in patients with antiphospholipid syndrome - single centre observational study in the United Kingdom. Semin Thromb Hemost 2022; DOI: 10.1055/s-0042-1757633.
  • 80 Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RF. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991; 66 (06) 629-632
  • 81 Sciascia S, Radin M, Cecchi I. et al. Reliability of lupus anticoagulant and anti-phosphatidylserine/prothrombin autoantibodies in antiphospholipid syndrome: a multicenter study. Front Immunol 2019; 10: 376
  • 82 Arnout J. Antiphospholipid syndrome: diagnostic aspects of lupus anticoagulants. Thromb Haemost 2001; 86 (01) 83-91
  • 83 Sciascia S, Sanna G, Khamashta MA. et al; APS Action. The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: a systematic review. Ann Rheum Dis 2015; 74 (11) 2028-2033
  • 84 Andreoli L, Chighizola CB, Banzato A, Pons-Estel GJ, Ramire de Jesus G, Erkan D. Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Arthritis Care Res (Hoboken) 2013; 65 (11) 1869-1873
  • 85 Cervera R, Serrano R, Pons-Estel GJ. et al; Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies). Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 2015; 74 (06) 1011-1018
  • 86 Pierangeli SS, Harris EN. Induction of phospholipid-binding antibodies in mice and rabbits by immunization with human beta 2 glycoprotein 1 or anticardiolipin antibodies alone. Clin Exp Immunol 1993; 93 (02) 269-272
  • 87 Salmon JE, Girardi G. Antiphospholipid antibodies and pregnancy loss: a disorder of inflammation. J Reprod Immunol 2008; 77 (01) 51-56
  • 88 Out HJ, Kooijman CD, Bruinse HW, Derksen RH. Histopathological findings in placentae from patients with intra-uterine fetal death and anti-phospholipid antibodies. Eur J Obstet Gynecol Reprod Biol 1991; 41 (03) 179-186
  • 89 Girardi G, Salmon JB. The role of complement in pregnancy and fetal loss. Autoimmunity 2003; 36 (01) 19-26
  • 90 Salmon JE, Girardi G, Holers VM. Activation of complement mediates antiphospholipid antibody-induced pregnancy loss. Lupus 2003; 12 (07) 535-538
  • 91 Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004; 10 (11) 1222-1226
  • 92 Cervera R, Asherson RA, Font J. Catastrophic antiphospholipid syndrome. Rheum Dis Clin North Am 2006; 32 (03) 575-590
  • 93 Aguiar CL, Erkan D. Catastrophic antiphospholipid syndrome: how to diagnose a rare but highly fatal disease. Ther Adv Musculoskelet Dis 2013; 5 (06) 305-314
  • 94 Bingley PJ, Hoffbrand BI. Antiphospholipid antibody syndrome: a review. J R Soc Med 1987; 80 (07) 445-448
  • 95 Rosove MH, Brewer PM. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992; 117 (04) 303-308
  • 96 Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332 (15) 993-997
  • 97 Crowther MA, Ginsberg JS, Julian J. et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349 (12) 1133-1138
  • 98 Finazzi G, Marchioli R, Brancaccio V. et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005; 3 (05) 848-853
  • 99 Levine SR, Brey RL, Tilley BC. et al; APASS Investigators. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004; 291 (05) 576-584
  • 100 Cohen H, Hunt BJ, Efthymiou M. et al; RAPS Trial Investigators. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematol 2016; 3 (09) e426-e436
  • 101 Pengo V, Denas G, Zoppellaro G. et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 2018; 132 (13) 1365-1371
  • 102 Woller SC, Stevens SM, Kaplan D. et al. Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial. Blood Adv 2022; 6 (06) 1661-1670
  • 103 Dufrost V, Wahl D, Zuily S. Direct oral anticoagulants in antiphospholipid syndrome: meta-analysis of randomized controlled trials. Autoimmun Rev 2021; 20 (01) 102711
  • 104 Cerdà P, Becattini C, Iriarte A, Hernández JC, Corbella X, Riera-Mestre A. Direct oral anticoagulants versus vitamin K antagonists in antiphospholipid syndrome: a meta-analysis. Eur J Intern Med 2020; 79: 43-50
  • 105 Ordi-Ros J, Sáez-Comet L, Pérez-Conesa M. et al. Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial. Ann Intern Med 2019; 171 (10) 685-694
  • 106 Arachchillage DRJ, Gomez K, Alikhan R, Anderson JAM, Lester W, Laffan M. British Society for Haematology Haemostasis and Thrombosis Taskforce. Addendum to British Society for Haematology Guidelines on Investigation and Management of Antiphospholipid syndrome, 2012 (Br. J. Haematol. 2012; 157: 47-58): use of direct acting oral anticoagulants. Br J Haematol 2020; 189 (02) 212-215
  • 107 Khairani CD, Bejjani A, Piazza G. et al. Direct oral anticoagulants vs vitamin-K antagonists in thrombotic antiphospholipid syndrome: meta-analysis of randomized controlled trials. J Am Coll Cardiol 2022; S0735-1097 (22)07098-X
  • 108 Arachchillage DRJ, Laffan M. Pathogenesis and management of antiphospholipid syndrome. Br J Haematol 2017; 178 (02) 181-195
  • 109 Schmidt-Tanguy A, Voswinkel J, Henrion D. et al. Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients. J Thromb Haemost 2013; 11 (10) 1927-1929
  • 110 EMA OdE. Accessed November 18, 2022 at:
  • 111 Rai RS, Clifford K, Cohen H, Regan L. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Hum Reprod 1995; 10 (12) 3301-3304
  • 112 Laskin CA, Bombardier C, Hannah ME. et al. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. N Engl J Med 1997; 337 (03) 148-153
  • 113 Triolo G, Ferrante A, Ciccia F. et al. Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. Arthritis Rheum 2003; 48 (03) 728-731
  • 114 Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997; 314 (7076): 253-257
  • 115 Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 2002; 100 (03) 408-413
  • 116 Jayakody Arachchillage D, Greaves M. The chequered history of the antiphospholipid syndrome. Br J Haematol 2014; 165 (05) 609-617
  • 117 Carmi O, Berla M, Shoenfeld Y, Levy Y. Diagnosis and management of catastrophic antiphospholipid syndrome. Expert Rev Hematol 2017; 10 (04) 365-374
  • 118 Rodríguez-Pintó I, Espinosa G, Erkan D, Shoenfeld Y, Cervera R. CAPS Registry Project Group. The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients. Rheumatology (Oxford) 2018; 57 (07) 1264-1270
  • 119 Ruffatti A, Del Ross T, Ciprian M. et al; Antiphospholipid Syndrome Study Group of Italian Society of Rheumatology. Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. Ann Rheum Dis 2011; 70 (06) 1083-1086
  • 120 Pengo V, Ruffatti A, Legnani C. et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood 2011; 118 (17) 4714-4718
  • 121 Erkan D, Harrison MJ, Levy R. et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum 2007; 56 (07) 2382-2391
  • 122 Sciascia S, Radin M, Cecchi I. et al. Open-label, prospective, phase II descriptive pilot trial of belimumab therapy for refractory and/or non-criteria manifestations of antiphospholipid syndrome: study protocol. Clin Exp Rheumatol 2022; DOI: 10.55563/clinexprheumatol/qa2yb4.